RU2015141278A - Новое производное 3-(4-(бензилокси)фенил)гекс-4-иновой кислоты, способ его получения и фармацевтическая композиция для профилактики и лечения метаболического заболевания, включающая его в качестве эффективного ингредиента - Google Patents
Новое производное 3-(4-(бензилокси)фенил)гекс-4-иновой кислоты, способ его получения и фармацевтическая композиция для профилактики и лечения метаболического заболевания, включающая его в качестве эффективного ингредиента Download PDFInfo
- Publication number
- RU2015141278A RU2015141278A RU2015141278A RU2015141278A RU2015141278A RU 2015141278 A RU2015141278 A RU 2015141278A RU 2015141278 A RU2015141278 A RU 2015141278A RU 2015141278 A RU2015141278 A RU 2015141278A RU 2015141278 A RU2015141278 A RU 2015141278A
- Authority
- RU
- Russia
- Prior art keywords
- phenyl
- benzyloxy
- hex
- formula
- compound represented
- Prior art date
Links
- -1 BENZYLOXY Chemical class 0.000 title claims 45
- 239000002253 acid Substances 0.000 title claims 40
- 208000016097 disease of metabolism Diseases 0.000 title claims 5
- 208000030159 metabolic disease Diseases 0.000 title claims 5
- 238000004519 manufacturing process Methods 0.000 title claims 4
- 239000008194 pharmaceutical composition Substances 0.000 title claims 4
- 230000002265 prevention Effects 0.000 title claims 4
- 150000001875 compounds Chemical class 0.000 claims 45
- 238000006243 chemical reaction Methods 0.000 claims 17
- 229910052757 nitrogen Inorganic materials 0.000 claims 15
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims 12
- 125000005842 heteroatom Chemical group 0.000 claims 12
- 229910052760 oxygen Inorganic materials 0.000 claims 12
- 229910052717 sulfur Inorganic materials 0.000 claims 12
- 229910052736 halogen Inorganic materials 0.000 claims 10
- 150000002367 halogens Chemical class 0.000 claims 10
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 10
- 125000003118 aryl group Chemical group 0.000 claims 9
- 125000003545 alkoxy group Chemical group 0.000 claims 8
- 125000000217 alkyl group Chemical group 0.000 claims 8
- 125000004429 atom Chemical group 0.000 claims 8
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 claims 7
- 125000001072 heteroaryl group Chemical group 0.000 claims 7
- 235000019766 L-Lysine Nutrition 0.000 claims 5
- 239000004472 Lysine Substances 0.000 claims 5
- 230000003287 optical effect Effects 0.000 claims 5
- 150000003839 salts Chemical class 0.000 claims 5
- 125000006713 (C5-C10) cycloalkyl group Chemical group 0.000 claims 4
- 125000000753 cycloalkyl group Chemical group 0.000 claims 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 4
- 238000006722 reduction reaction Methods 0.000 claims 4
- 125000002947 alkylene group Chemical group 0.000 claims 3
- 229910052799 carbon Inorganic materials 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims 2
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims 2
- 125000000623 heterocyclic group Chemical group 0.000 claims 2
- 150000002825 nitriles Chemical class 0.000 claims 2
- 125000001424 substituent group Chemical group 0.000 claims 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 2
- 125000000081 (C5-C8) cycloalkenyl group Chemical group 0.000 claims 1
- 125000004203 4-hydroxyphenyl group Chemical group [H]OC1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 125000000041 C6-C10 aryl group Chemical group 0.000 claims 1
- 208000032928 Dyslipidaemia Diseases 0.000 claims 1
- 102000004190 Enzymes Human genes 0.000 claims 1
- 108090000790 Enzymes Proteins 0.000 claims 1
- 102100026148 Free fatty acid receptor 1 Human genes 0.000 claims 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 1
- 101000912510 Homo sapiens Free fatty acid receptor 1 Proteins 0.000 claims 1
- 208000035150 Hypercholesterolemia Diseases 0.000 claims 1
- 208000031226 Hyperlipidaemia Diseases 0.000 claims 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims 1
- 206010022489 Insulin Resistance Diseases 0.000 claims 1
- 208000017170 Lipid metabolism disease Diseases 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 1
- 230000003213 activating effect Effects 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 claims 1
- 238000006482 condensation reaction Methods 0.000 claims 1
- 125000000392 cycloalkenyl group Chemical group 0.000 claims 1
- 239000008103 glucose Substances 0.000 claims 1
- 201000001421 hyperglycemia Diseases 0.000 claims 1
- 208000006575 hypertriglyceridemia Diseases 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 229910052708 sodium Inorganic materials 0.000 claims 1
- 239000011734 sodium Substances 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical compound [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
- C07C51/347—Preparation of carboxylic acids or their salts, halides or anhydrides by reactions not involving formation of carboxyl groups
- C07C51/367—Preparation of carboxylic acids or their salts, halides or anhydrides by reactions not involving formation of carboxyl groups by introduction of functional groups containing oxygen only in singly bound form
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
- C07C51/347—Preparation of carboxylic acids or their salts, halides or anhydrides by reactions not involving formation of carboxyl groups
- C07C51/373—Preparation of carboxylic acids or their salts, halides or anhydrides by reactions not involving formation of carboxyl groups by introduction of functional groups containing oxygen only in doubly bound form
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/40—Unsaturated compounds
- C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
- C07C59/72—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings and other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/40—Unsaturated compounds
- C07C59/76—Unsaturated compounds containing keto groups
- C07C59/90—Unsaturated compounds containing keto groups containing singly bound oxygen-containing groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/06—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with radicals, containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
- C07D211/14—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D211/70—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/84—Nitriles
- C07D213/85—Nitriles in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/04—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to the ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/04—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to the ring carbon atoms
- C07D215/06—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to the ring carbon atoms having only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
- C07D217/04—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
- C07D217/24—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/20—Spiro-condensed ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
- C07D271/07—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D277/82—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/06—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by halogen atoms or nitro radicals
- C07D295/073—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by halogen atoms or nitro radicals with the ring nitrogen atoms and the substituents separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
- C07D295/096—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D295/155—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/72—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 spiro-condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/4035—Isoindoles, e.g. phthalimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/44—Iso-indoles; Hydrogenated iso-indoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/55—Acids; Esters
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/04—Ortho- or peri-condensed ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Quinoline Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Indole Compounds (AREA)
- Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Pyridine Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Pyrrole Compounds (AREA)
Claims (132)
1. Соединение, представленное приведенной ниже формулой 1, его оптический изомер или его фармацевтически приемлемая соль:
[Формула 1]
(в формуле 1,
A и E независимо обозначают C, N или O;
n означает целое число 0-5;
X обозначает простую связь или C1-10 прямой или разветвленный алкилен;
R1 обозначает -H, -ОН, галоген, C1-10 прямой или разветвленный алкил, C1-10 прямой или разветвленный алкокси, C5-10 циклоалкил или C5-10 циклоалкенил;
R2, R3 и R5 независимо обозначают -H, -ОН, галоген, C1-10 прямой или разветвленный алкил или C1-10 прямой или разветвленный алкокси;
причем R2 и R3 могут образовывать C5-10 циклоалкил, C6-10 арил, 5-10-членный гетероциклоалкил или 5-10-членный гетероарил вместе с атомами, которые к ним присоединены. 5-10-членный гетероциклоалкил может содержать один или более гетероатомов, выбранных из группы, состоящей из N, O и S, и 5-10-членный гетероарил может содержать один или более гетероатомов, выбранных из группы, состоящей из N, O и S;
R4A обозначает -H, -ОН, =O, незамещенный или замещенный C6-10 арил или незамещенный или замещенный 5-10-членный гетероарил, содержащий один или более гетероатомов, выбранных из группы, состоящей из N, O и S,
в упомянутом замещенном C6-10 ариле и замещенном 5-10-членном гетероариле один или более заместителей, выбранных из группы, состоящей из -ОН, галогена, нитрила, незамещенного или замещенного C1-5 прямого или разветвленного алкила, в котором один или более галогенов замещены, незамещенного или замещенного C1-5 прямого или разветвленного алкокси, в котором один или более галогенов замещены, C1-10 прямого или разветвленного алкилсульфонила, , и могут быть замещены, причем m и q независимо означают целые числа 1-10,
в упомянутом незамещенном или замещенном 5-10-членном гетероариле фенил может быть конденсирован;
причем R3 и R4A могут образовывать C5-10 циклоалкил, C6-10 арил, 5-10-членный гетероциклоалкил или 5-10-членный гетероарил вместе с атомами, которые к нему присоединены. 5-10-членный гетероциклоалкил может содержать один или более гетероатомов, выбранных из группы, состоящей из N, O и S, и 5-10-членный гетероарил может содержать один или более гетероатомов, выбранных из группы, состоящей из N, O и S;
в упомянутом C5-10 циклоалкиле, C6-10 ариле, 5-10-членном гетероциклоалкиле и 5-10-членном гетероариле, C1-5 прямой или разветвленный алкокси может быть замещен;
R4B отсутствует или может образовывать 5-10-членный гетероцикл, содержащий один или более гетероатомов, выбранных из группы, состоящей из N, O и S, вместе с атомами, которые к нему присоединены, и R4A).
2. Соединение, представленное формулой 1, его оптический изомер или его фармацевтически приемлемая соль по п. 1, в котором:
обозначает простую связь или двойную связь;
A и E независимо обозначают C, N или O;
n означает целое число 0-3;
X обозначает простую связь или C1-5 прямой или разветвленный алкилен;
R1 обозначает -H, -OH, галоген, C1-5 прямой или разветвленный алкил, C1-5 прямой или разветвленный алкокси, C5-8 циклоалкил или C5-8 циклоалкенил;
R2, R3 и R5 независимо обозначают -H, -OH, галоген, C1-5 прямой или разветвлены алкил или C1-5 прямой или разветвленный алкокси;
причем R2 и R3 могут образовывать C5-8 циклоалкил, C6-8 арил, 5-8-членный гетероциклоалкил или 5-8-членный гетероарил вместе с атомами, которые к ним присоединены; 5-8-членный гетероциклоалкил может содержать один или более гетероатомов, выбранных из группы, состоящей из N, O и S, и 5-8-членный гетероарил может содержать один или более гетероатомов, выбранных из группы, состоящей из N, O и S;
R4A обозначает -H, -OH, =O, незамещенный или замещенный C6-8 арил или незамещенный или замещенный 5-8-членный гетероарил, содержащий один или более гетероатомов, выбранных из группы, состоящей из N, O и S,
в упомянутом замещенном C6-8 ариле и замещенном 5-8-членном гетероариле один или более заместителей, выбранных из группы, состоящей из -OH, галогена, нитрила, незамещенного или замещенного C1-5 прямого или разветвленного алкила, в котором один или более галогенов замещены, незамещенного или замещенного C1-5 прямого или разветвленного алкокси, в котором один или более галогенов замещены, C1-8 прямого или разветвленного алкилсульфонила, и могут быть замещены; причем m и q независимо означают целые числа 1-5,
в упомянутом незамещенном или замещенном 5-8-членном гетероариле фенил может быть конденсирован;
причем R3 и R4A могут образовывать C5-8 циклоалкил, C6-8 арил, 5-8-членный гетероциклоалкил или 5-8-членный гетероарил вместе с атомами, которые к ним присоединены; 5-8-членный гетероциклоалкил может содержать один или более гетероатомов, выбранных из группы, состоящей из N, O и S, и 5-8-членный гетероарил может содержать один или более гетероатомов, выбранных из группы, состоящей из N, O и S;
в упомянутом C5-8 циклоалкиле, C6-8 ариле, 5-8-членном гетероциклоалкиле и 5-8-членном гетероариле C1-5 прямой или разветвленный алкокси может быть замещен;
R4B отсутствует или может образовывать 5-8-членный гетероцикл, содержащий один или более гетероатомов, выбранных из группы, состоящей из N, O и S, вместе с атомами, которые к нему присоединены, и R4A.
3. Соединение, представленное формулой 1, его оптический изомер или его фармацевтически приемлемая соль по п. 1, в котором:
обозначает простую связь или двойную связь;
A и E независимо обозначают C или N;
n означает целое число 0-1;
X обозначает простую связь или C1-3 прямой или разветвленный алкилен;
R2, R3 и R5 независимо обозначают -H,
причем R2 и R3 могут образовывать фенил;
причем R3 и R4A могут образовывать фенил вместе с атомами, которые к ним присоединены; в упомянутом фениле метокси может быть замещен;
4. Соединение, представленное формулой 1, его оптический изомер или его фармацевтически приемлемая соль по п. 1, причем соединение, представленное формулой 1, выбрано из группы, состоящей из следующих соединений:
(1) 3-(4-(3-(1,4-диоксаспиро[4,5]дец-7-ен-8-ил)бензилокси)фенил)гекс-4-иновая кислота;
(2) L-лизин 3-(4-(3-(1,4-диоксаспиро[4,5]дец-7-ен-8-ил)бензилокси)фенил)гекс-4-иноат;
(3) 4-(4-(3-(1,4-диоксаспиро[4,5]дец-7-ен-8-ил)бензилокси)фенил)гекс-4-иновая кислота;
(4) 3-(4-(3-(4-оксоциклогекс-1-енил)бензилокси)фенил)гекс-4-иновая кислота;
(5) 3-(4-(3-(4-гидроксициклогекс-1-енил)бензилокси)фенил)гекс-4-иновая кислота;
(6) L-лизин 3-(4-(3-(4-гидроксициклогекс-1-енил)бензилокси)фенил)гекс-4-иноат;
(7) (3S)-3-(4-(3-(1,4-диоксаспиро[4,5]дец-7-ен-8-ил)бензилокси)фенил)гекс-4-иновая кислота;
(8) (3R)-3-(4-(3-(1,4-диоксаспиро[4,5]дец-7-ен-8-ил)бензилокси)фенил)гекс-4-иновая кислота;
(9) L-лизин (3S)-3-(4-(3-(1,4-диоксаспиро[4,5]дец-7-ен-8-ил)бензилокси)фенил)гекс-4-иноат;
(10) L-лизин (3R)-3-(4-(3-(1,4-диоксаспиро[4,5]дец-7-ен-8-ил)бензилокси)фенил)гекс-4-иноат;
(11) (3S)-3-(4-(3-(1,4-диоксаспиро[4,5]дец-7-ен-8-ил)бензилокси)фенил)гекс-4-иноат натрия;
(12) 3-(4-(4-((3,4-дигидроизохинолин-2(1H)-ил)метил)бензилокси)фенил)гекс-4-иновая кислота;
(13) 3-(4-(3-циклогексенил-4-((3,4-дигидроизохинолин-2(1H)-ил)метил)бензилокси)фенил)гекс-4-иновая кислота;
(14) 3-(4-(4-((4-фенил-5,6-дигидропиридин-1(2H)-ил)метил)бензилокси)фенил)гекс-4-иновая кислота;
(15) 3-(4-(4-((4-фенилпиперазин-1-ил)метил)бензилокси)фенил)гекс-4-иновая кислота;
(16) 3-(4-(4-((6-метокси-3,4-дигидроизохинолин-2(1H)-ил)метил)бензилокси)фенил)гекс-4-иновая кислота;
(17) 3-(4-(4-((4-фенилпиперидин-1-ил)метил)бензилокси)фенил)гекс-4-иновая кислота;
(18) 3-(4-(4-((4-(4-фторфенил)пиперазин-1-ил)метил)бензилокси)фенил)гекс-4-иновая кислота;
(19) 3-(4-(4-((4-(4-(трифторметил)фенил)пиперазин-1-ил)метил)бензилокси)фенил)гекс-4-иновая кислота;
(20) 3-(4-(4-((4-(4-(3-(метилсульфонил)пропокси)фенил)пиперазин-1-ил)метил)бензилокси)фенил)гекс-4-иновая кислота;
(21) (S)-3-(4-(4-((3,4-дигидроизохинолин-2(1H)-ил)метил)бензилокси)фенил)гекс-4-иновая кислота;
(22) (S)-3-(4-(4-((4-(4-(трифторметил)фенил)пиперазин-1-ил)метил)бензилокси)фенил)гекс-4-иновая кислота;
(23) (S)-3-(4-(4-((4-(4-фторфенил)пиперазин-1-ил)метил)бензилокси)фенил)гекс-4-иновая кислота;
(24) (S)-3-(4-(4-((4-(4-(трифторметил)фенил)пиперазин-1-ил)метил)бензилокси)фенил)гекс-4-иноат калия;
(25) (S)-3-(4-(4-((6-метокси-3,4-дигидроизохинолин-2(1H)-ил)метил)бензилокси)фенил)гекс-4-иновая кислота;
(26) (S)-3-(4-(4-((4-фенилпиперидин-1-ил)метил)бензилокси)фенил)гекс-4-иновая кислота;
(27) (S)-3-(4-(4-(изоиндолин-2-илметил)бензилокси)фенил)гекс-4-иновая кислота;
(28) (S)-3-(4-(4-((4-фенил-5,6-дигидропиридин-1(2H)-ил)метил)бензилокси)фенил)гекс-4-иновая кислота;
(29) (S)-3-(4-(4-((4-(4-(метоксиметокси)фенил)пиперазин-1-ил)метил)бензилокси)фенил)гекс-4-иновая кислота;
(30) (S)-3-(4-(4-((4-(5-изопропил-1,2,4-оксадиазол-3-ил)пиперидин-1-ил)метил)бензилокси)фенил)гекс-4-иновая кислота;
(31) (S)-3-(4-(4-((4-(5-изопропил-1,2,4-оксадиазол-3-ил)пиперазин-1-ил)метил)бензилокси)фенил)гекс-4-иновая кислота;
(32) (S)-3-(4-(4-((4-(4-(метилсульфонил)фенил)-5,6-дигидропиридин-1(2H)-ил)метил)бензилокси)фенил)гекс-4-иновая кислота;
(33) (S)-3-(4-(4-((4-(4-(3-(метилсульфонил)пропокси)фенил)-5,6-дигидропиридин-1(2H)-ил)метил)бензилокси)фенил)гекс-4-иновая кислота;
(34) (3S)-3-(4-(4-(1-(3,4-дигидроизохинолин-2(1H)-ил)этил)бензилокси)фенил)гекс-4-иновая кислота;
(35) (S)-3-(4-(4-((4-(4-гидроксифенил)пиперазин-1-
ил)метил)бензилокси)фенил)гекс-4-иновая кислота;
(36) (S)-3-(4-(4-((4-(4-(3-(метилсульфонил)пропокси)фенил)пиперазин-1-ил)метил)бензилокси)фенил)гекс-4-иновая кислота;
(37) (S)-3-(4-(4-(изоиндолин-2-илметил)бензилокси)фенил)гекс-4-иноат натрия;
(38) L-лизин (S)-3-(4-(4-(изоиндолин-2-илметил)бензилокси)фенил)гекс-4-иноат;
(39) (S)-3-(4-(4-((4-(4-фторфенил)-5,6-дигидропиридин-1(2H)-ил)метил)бензилокси)фенил)гекс-4-иновая кислота;
(40) (S)-3-(4-(4-((4-(4-метоксифенил)пиперазин-1-ил)метил)бензилокси)фенил)гекс-4-иновая кислота;
(41) (S)-3-(4-(4-((3,4-дигидрохинолин-1(2H)-ил)метил)бензилокси)фенил)гекс-4-иноат натрия;
(42) (S)-3-(4-(4-((3,4-дигидрохинолин-1(2H)-ил)метил)бензилокси)фенил)гекс-4-иноат калия;
(43) (S)-3-(4-(4-((4-(бензо[d]тиазол-2-ил)пиперазин-1-ил)метил)бензилокси)фенил)гекс-4-иновая кислота;
(44) (S)-3-(4-(4-((4-(5-пропилпиримидин-2-ил)пиперазин-1-ил)метил)бензилокси)фенил)гекс-4-иновая кислота;
(45) (S)-3-(4-(4-((4-(5-цианопиридин-2-ил)пиперазин-1-ил)метил)бензилокси)фенил)гекс-4-иновая кислота;
(46) (3S)-3-(4-(4-((3-фенилпирролидин-1-ил)метил)бензилокси)фенил)гекс-4-иновая кислота;
(47) (S)-3-(4-(4-((4-(4-метоксифенил)пиперазин-1-ил)метил)бензилокси)фенил)гекс-4-иноат натрия;
(48) (S)-3-(4-(4-(2-(6-метокси-3,4-дигидроизохинолин-2(1H)-ил)этил)бензилокси)фенил)гекс-4-иновая кислота;
(49) (S)-3-(4-(4-(2-(изоиндолин-2-ил)этил)бензилокси)фенил)гекс-4-иновая кислота;
(50) (S)-3-(4-(4-(2-(3,4-дигидроизохинолин-2(1H)-ил)этил)бензилокси)фенил)гекс-4-иновая кислота; и
(51) (S)-3-(4-(4-((6-метокси-3,4-дигидроизохинолин-2(1H)-ил)метил)бензилокси)фенил)гекс-4-иноат натрия.
5. Способ получения соединения, представленного формулой 1 по п. 1, включающий следующие стадии, как показано в приведенной ниже схеме реакции 1:
получение соединения, представленного формулой 4, реакцией конденсации соединения, представленного формулой 2, и соединения, представленного формулой 3 (стадия 1); и
получение соединения, представленного формулой 1, реакцией восстановления соединения, представленного формулой 4, полученного на стадии 1 (стадия 2).
[Схема Реакции 1]
(в схеме реакции 1,
R1, R2, R3, R4A, R4B, R5, A, E, n и X имеют значения, определенные в формуле 1; и Y обозначает C1-10 прямой или разветвленный алкил).
6. Способ получения соединения, представленного формулой 1 по п. 1, в котором соединение, представленное формулой 2, получают способом, включающим следующие стадии, как показано в приведенной ниже схеме реакции 2:
получение соединения, представленного формулой 10, путем реакции соединения, представленного формулой 8, и соединения, представленного формулой 9 (стадия 1);
получение соединения, представленного формулой 12, реакцией соединения, представленного формулой 10, полученного на стадии 1, и соединения, представленного формулой 11 (стадия 2); и
получение соединения, представленного формулой 2, реакцией восстановления соединения, представленного формулой 12, полученного на стадии 2 (стадия 3).
[Схема реакции 2]
(В схеме реакции 2,
R1, R2, R3, R4A, R4B, R5, A, E, n и X имеют значения, определенные в формуле 1; и -OTf обозначает трифторметансульфонат).
7. Способ получения соединения, представленного формулой 1 по п. 1, включающий следующие стадии, как показано в приведенной ниже схеме реакции 3:
получение соединения, представленного формулой 6, реакцией сочетания соединения, представленного формулой 5, и соединения, представленного формулой 3 (стадия 1);
получение соединения, представленного формулой 7, мезилатной реакцией соединения, представленного формулой 6, полученного на стадии 1 (стадия 2);
получение соединения, представленного формулой 4, путем замены мезилатной части соединения, представленного формулой 7, полученного на стадии 2, соединением, представленным формулой 13 (стадия 3); и
получение соединения, представленного формулой 1, реакцией восстановления соединения, представленного формулой 4, полученного на стадии 3 (стадия 4).
[Схема реакции 3]
(В схеме реакции 3
R1, R2, R3, R4A, R4B, R5, A, E, n и X имеют значения, определенные в формуле 1; и Y обозначает C1-10 прямой или разветвленный алкил).
8. Способ получения соединения, представленного формулой 1 по п. 1, включающий стадию получения соединения, представленного формулой 1b, реакцией размыкания кольца соединения, представленного формулой 1a (стадия 1), как показано в приведенной ниже схеме реакции 4:
[Схема реакции 4]
(В схеме реакции 4
R1 имеет значения, определенные в формуле 1; и соединения, представленные формулой 1a и формулой 1b, включены в соединение, представленное формулой 1).
9. Способ получения соединения, представленного формулой 1 по п. 1, включающий стадию получения соединения, представленного формулой 1c, реакцией восстановления соединения, представленного формулой 1b (стадия 1), как показано в приведенной ниже схеме реакции 5:
[Схема реакции 5]
(В схеме реакции 5
R1 имеет значения, определенные в формуле 1; и соединения, представленные формулой 1b и формулой 1c, включены в соединение, представленное формулой 1).
10. Фармацевтическая композиция, включающая соединение, представленное формулой 1 по п. 1, его оптический изомер или его фармацевтически приемлемую соль в качестве активного ингредиента для профилактики или лечения метаболического заболевания.
11. Фармацевтическая композиция для профилактики или лечения метаболического заболевания по п. 10, причем соединение характеристически способно активировать фермент GPR40.
12. Фармацевтическая композиция для профилактики или лечения метаболического заболевания по п. 10, причем метаболическое заболевание выбрано из группы, состоящей из ожирения, диабета типа 1, диабета типа II, несовместимой переносимости глюкозы, инсулинорезистентности, гипергликемии, гиперлипидемии, гипертриглицеридемии, гиперхолестеринемии, дислипидемии и синдрома X.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20130043100 | 2013-04-18 | ||
KR10-2013-0043100 | 2013-04-18 | ||
KR10-2014-0045343 | 2014-04-16 | ||
KR1020140045343A KR101569522B1 (ko) | 2013-04-18 | 2014-04-16 | 신규한 3-(4-(벤질옥시)페닐)헥스-4-이노익 산 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 대사성 질환의 예방 또는 치료용 약학적 조성물 |
PCT/KR2014/003355 WO2014171762A1 (ko) | 2013-04-18 | 2014-04-17 | 신규한 3-(4-(벤질옥시)페닐)헥스-4-이노익 산 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 대사성 질환의 예방 또는 치료용 약학적 조성물 |
Publications (2)
Publication Number | Publication Date |
---|---|
RU2015141278A true RU2015141278A (ru) | 2017-05-25 |
RU2628077C2 RU2628077C2 (ru) | 2017-08-14 |
Family
ID=51995678
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2015141278A RU2628077C2 (ru) | 2013-04-18 | 2014-04-17 | Новое производное 3-(4-(бензилокси)фенил)гекс-4-иновой кислоты, способ его получения и фармацевтическая композиция для профилактики и лечения метаболического заболевания, включающая его в качестве эффективного ингредиента |
Country Status (16)
Country | Link |
---|---|
US (1) | US9969723B2 (ru) |
EP (1) | EP2987791B1 (ru) |
JP (2) | JP6174784B2 (ru) |
KR (1) | KR101569522B1 (ru) |
CN (1) | CN105121423B (ru) |
AU (1) | AU2014254555B2 (ru) |
BR (1) | BR112015025072B1 (ru) |
CA (1) | CA2908398C (ru) |
DK (1) | DK2987791T3 (ru) |
ES (1) | ES2745746T3 (ru) |
HK (1) | HK1214822A1 (ru) |
MX (1) | MX367769B (ru) |
PL (1) | PL2987791T3 (ru) |
PT (1) | PT2987791T (ru) |
RU (1) | RU2628077C2 (ru) |
WO (1) | WO2014171762A1 (ru) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105722841A (zh) * | 2013-11-14 | 2016-06-29 | 卡迪拉保健有限公司 | 新型杂环化合物 |
CN111423408A (zh) * | 2014-10-17 | 2020-07-17 | 现代药品株式会社 | 代谢性疾病的预防或治疗用复合制剂 |
CN109516914A (zh) * | 2017-09-20 | 2019-03-26 | 华东师范大学 | 苯丙炔酸类小分子有机化合物及其合成方法和用途 |
SG11202004891PA (en) * | 2017-12-01 | 2020-06-29 | Hyundai Pharm Co Ltd | Novel use of 3-(4-(benzyloxy)phenyl)hex-4-inoic acid derivative |
CN110092774B (zh) * | 2018-01-29 | 2022-04-08 | 中国科学院上海药物研究所 | 芳香丙酸类衍生物、及其制备方法和用途 |
CA3091015C (en) | 2018-02-13 | 2023-02-21 | Gilead Sciences, Inc. | Pd-1/pd-l1 inhibitors |
US10899735B2 (en) | 2018-04-19 | 2021-01-26 | Gilead Sciences, Inc. | PD-1/PD-L1 inhibitors |
JP7105359B2 (ja) | 2018-07-13 | 2022-07-22 | ギリアード サイエンシーズ, インコーポレイテッド | Pd-1/pd-l1阻害剤 |
WO2020086556A1 (en) | 2018-10-24 | 2020-04-30 | Gilead Sciences, Inc. | Pd-1/pd-l1 inhibitors |
JP7297199B2 (ja) | 2019-02-04 | 2023-06-26 | 美里工業株式会社 | 電動格納式車両用周辺視認装置 |
US20220213051A1 (en) * | 2019-05-31 | 2022-07-07 | Hyundai Pharm Co., Ltd. | Novel crystal form of 3-(4-(benzyloxy)phenyl)hex-4-inoic acid derivative |
KR102270026B1 (ko) * | 2020-01-31 | 2021-06-28 | 현대약품 주식회사 | (3s)-3-(4-(3-(1,4-다이옥사스파이로[4,5]데스-7-엔-8-일)벤질옥시)페닐)헥스-4-이노익산의 품질 평가 방법 |
KR20220136800A (ko) * | 2021-04-01 | 2022-10-11 | 현대약품 주식회사 | 3-(4-(벤질옥시)페닐)헥스-4-이노익산 유도체의 신규 용도 |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4345230B2 (ja) | 1998-03-10 | 2009-10-14 | 小野薬品工業株式会社 | カルボン酸誘導体およびその誘導体を有効成分として含有する薬剤 |
GB0214149D0 (en) | 2002-06-19 | 2002-07-31 | Glaxo Group Ltd | Chemical compounds |
ES2433466T3 (es) | 2004-02-27 | 2013-12-11 | Amgen, Inc | Compuestos, composiciones farmacéuticas y métodos para su uso en el tratamiento de trastornos metabólicos |
EP1731505B1 (en) | 2004-03-30 | 2015-01-14 | Takeda Pharmaceutical Company Limited | Alkoxyphenylpropanoic acid derivatives |
WO2008030618A1 (en) * | 2006-09-07 | 2008-03-13 | Amgen Inc. | Benzo-fused compounds for use in treating metabolic disorders |
EP2064193A1 (en) * | 2006-09-07 | 2009-06-03 | Amgen, Inc | Heterocyclic gpr40 modulators |
US7572934B2 (en) * | 2007-04-16 | 2009-08-11 | Amgen Inc. | Substituted biphenyl GPR40 modulators |
KR20100090249A (ko) * | 2007-10-10 | 2010-08-13 | 암젠 인크 | 치환된 비페닐 grp40 조절제 |
US8299296B2 (en) * | 2007-10-26 | 2012-10-30 | Japan Tobacco Inc. | Spiro compounds and pharmaceutical use thereof |
EP2260017A1 (en) * | 2008-03-06 | 2010-12-15 | Amgen, Inc | Conformationally constrained carboxylic acid derivatives useful for treating metabolic disorders |
AR078522A1 (es) * | 2009-10-15 | 2011-11-16 | Lilly Co Eli | Compuesto de espiropiperidina, composicion farmaceutica que lo comprende, su uso para preparar un medicamento util para tratar diabetes y compuesto intermediario para su sintesis |
CN105722841A (zh) * | 2013-11-14 | 2016-06-29 | 卡迪拉保健有限公司 | 新型杂环化合物 |
-
2014
- 2014-04-16 KR KR1020140045343A patent/KR101569522B1/ko active IP Right Grant
- 2014-04-17 ES ES14786040T patent/ES2745746T3/es active Active
- 2014-04-17 AU AU2014254555A patent/AU2014254555B2/en active Active
- 2014-04-17 BR BR112015025072-6A patent/BR112015025072B1/pt active IP Right Grant
- 2014-04-17 RU RU2015141278A patent/RU2628077C2/ru active
- 2014-04-17 PT PT147860407T patent/PT2987791T/pt unknown
- 2014-04-17 EP EP14786040.7A patent/EP2987791B1/en active Active
- 2014-04-17 DK DK14786040.7T patent/DK2987791T3/da active
- 2014-04-17 JP JP2016508871A patent/JP6174784B2/ja active Active
- 2014-04-17 WO PCT/KR2014/003355 patent/WO2014171762A1/ko active Application Filing
- 2014-04-17 MX MX2015013893A patent/MX367769B/es active IP Right Grant
- 2014-04-17 PL PL14786040T patent/PL2987791T3/pl unknown
- 2014-04-17 CN CN201480019721.5A patent/CN105121423B/zh active Active
- 2014-04-17 CA CA2908398A patent/CA2908398C/en active Active
-
2015
- 2015-10-01 US US14/872,745 patent/US9969723B2/en active Active
-
2016
- 2016-03-10 HK HK16102795.5A patent/HK1214822A1/zh unknown
-
2017
- 2017-04-07 JP JP2017076799A patent/JP2017149747A/ja not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
PL2987791T3 (pl) | 2020-03-31 |
BR112015025072A2 (pt) | 2017-07-18 |
ES2745746T3 (es) | 2020-03-03 |
CN105121423A (zh) | 2015-12-02 |
MX2015013893A (es) | 2015-12-11 |
WO2014171762A1 (ko) | 2014-10-23 |
HK1214822A1 (zh) | 2016-08-05 |
EP2987791B1 (en) | 2019-07-17 |
KR101569522B1 (ko) | 2015-11-17 |
DK2987791T3 (da) | 2019-10-14 |
US9969723B2 (en) | 2018-05-15 |
MX367769B (es) | 2019-09-05 |
CN105121423B (zh) | 2017-06-09 |
JP2017149747A (ja) | 2017-08-31 |
EP2987791A1 (en) | 2016-02-24 |
JP6174784B2 (ja) | 2017-08-02 |
BR112015025072B1 (pt) | 2022-03-15 |
CA2908398A1 (en) | 2014-10-23 |
AU2014254555A1 (en) | 2015-10-29 |
PT2987791T (pt) | 2019-10-24 |
RU2628077C2 (ru) | 2017-08-14 |
US20160024063A1 (en) | 2016-01-28 |
AU2014254555B2 (en) | 2016-11-10 |
KR20140126248A (ko) | 2014-10-30 |
JP2016518366A (ja) | 2016-06-23 |
CA2908398C (en) | 2019-01-15 |
EP2987791A4 (en) | 2016-11-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2015141278A (ru) | Новое производное 3-(4-(бензилокси)фенил)гекс-4-иновой кислоты, способ его получения и фармацевтическая композиция для профилактики и лечения метаболического заболевания, включающая его в качестве эффективного ингредиента | |
JP4931893B2 (ja) | Ppar活性化化合物及びこれを含有する医薬組成物 | |
RU2019121871A (ru) | Новые производные фенилпропионовой кислоты и их применение | |
RU2361860C2 (ru) | Новые замещенные 3-сера-индолы | |
RU2007107189A (ru) | Производные арилпиридина | |
JP2009530281A5 (ru) | ||
JP2006520755A5 (ru) | ||
JP2008513516A5 (ru) | ||
NZ631569A (en) | Phenyl alkanoic acid derivatives as gpr agonists | |
RU2005136368A (ru) | Производные пиперазина и их применение для лечения неврологических и психиатрических заболеваний | |
JP2010529203A5 (ru) | ||
RU2009133259A (ru) | Производные пиразола в качестве ингибиторов 11-бета-hsd1 | |
RU2006138485A (ru) | 1,3,4-оксадиазол-2-оны в качестве модуляторов ppar-дельта и их применение | |
RU2013130925A (ru) | Оксимовые соединения в качестве средств для повышения уровня холестерина высокой плотности | |
EA016629B1 (ru) | 1,3-диоксанкарбоновые кислоты | |
JP2008530242A5 (ru) | ||
RU2009119421A (ru) | Производные 2-фенил-6-аминокарбонилпиримидина и их применение в качестве антагонистов тромбоцитарного рецептора адф (p2y12 рецептора) | |
RU2013130879A (ru) | Производные оксазолилметилового эфира в качестве агонистов рецептора alx | |
RU2008129641A (ru) | Ингибиторы ccr9 активности | |
JP2016506910A5 (ru) | ||
RU2006119503A (ru) | Етероарильные производные в качестве активаторов рецепторов, активируемых пролифераторами пероксисом (ppar) | |
JP2014031374A (ja) | キノリン類化合物及びその薬物組成物、製造方法並びに応用 | |
JP2007522178A5 (ru) | ||
JP2010504322A5 (ru) | ||
NO20072418L (no) | Arylsulfonylmetyl- eller arylsufonamidsubstituerte aromatiske forbindelser egnet for behandling av lidelser som reagerer pa modulering av dopamin D3-reseptoren |